Type1 Diabetes Clinical Trial
Official title:
Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD)
The main purpose of this study is to see if a drug called aldesleukin, can preserve insulin production in children and young adults recently diagnosed with type 1 diabetes. One group will receive aldesleukin and the other a placebo.
Investigators know that the longer people with diabetes can produce their own insulin, the better it is for the control of their blood glucose levels and long-term complications. People get type 1 diabetes because their immune system, the part of the body, which helps fight infections, mistakenly attacks and destroys the beta cells in the pancreas that produce insulin. As the immune system destroys these insulin-producing cells, the body's own ability to produce insulin decreases and diabetes develops. At diagnosis, there are usually a small number of beta cells (10-20%) left in the pancreas, which still produce small amounts of insulin. This is called 'beta cell function' and it is assessed by measuring C-peptide, which is a protein made by the pancreas when insulin is produced. Most people with type 1 diabetes eventually stop producing insulin themselves, this may occur rapidly in a few months, or more slowly over several years. New treatments preserving insulin production could improve management of diabetes. This could be done by using drugs acting on cells of the immune system. In type 1 diabetes, there is an imbalance between cells of the immune system, and there is evidence that one protein produced by our body, called Interleukin-2, could help in resetting the balance between those cells. It is important to start this treatment soon after diagnosis because this when there is the best chance of saving the beta cells still left in the pancreas. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05536232 -
Residual Insulin Secretion in Patients With Type 1 Diabetes Under a Low Carbohydrate Diet or a Ketogenic Diet
|
N/A | |
| Completed |
NCT04255381 -
Yale-Harvard Hotel-based Closed-Loop Studies in Children (HY-GRAID)
|
N/A | |
| Completed |
NCT04625595 -
Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes
|
Phase 1 | |
| Active, not recruiting |
NCT06177691 -
Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer): Extension Study
|
||
| Completed |
NCT04002557 -
Optimising Consultation Summaries to Promote Good Health
|
||
| Completed |
NCT05876273 -
Neural-net Artificial Pancreas (NAP)
|
N/A | |
| Withdrawn |
NCT03236558 -
The Role of the Thymus in Type I Diabetes.
|
N/A | |
| Completed |
NCT03179280 -
Effect of Dual-wave Insulin Bolus on Postprandial Glycaemia
|
N/A | |
| Recruiting |
NCT06253351 -
Real-world Use of Hybrid Closed Loop in Adolescents and Young Adults 15-25 Years of Age With Type 1 Diabetes
|
||
| Completed |
NCT01357603 -
Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM
|
Phase 1 | |
| Completed |
NCT04233034 -
Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes
|
Phase 3 | |
| Completed |
NCT04520971 -
Closed-loop Insulin Delivery in Pregnant Women With Type 1 Diabetes
|
N/A | |
| Recruiting |
NCT05766657 -
Evaluation of an Anti-inflammatory Diet in Autoimmune and Metabolic Diseases
|
N/A | |
| Completed |
NCT01838083 -
Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus
|
Phase 1 |